guideline and the shortly coming updated version is an appropriate time to review and compare it with other European guidelines in order to identify the main similarities and differences in key features. METHODS: We chose 14 European guidelines and compared them based on the 32 key guideline features developed by Hjelmgren et al. RESULTS: No relevant differences were found between the Hungarian and the European guidelines in tha major part (23) of the key features. The Hungarian guideline represented nearly the same methodological aspects for example in the choice of comparator, time horizon, discount rate and financial impact analysis. We appraised relevant differences in the perspective of the PE studies, preferred analytical technic (CMA, CEA, CUA, CBA), systematic review of evidences, costs to be included, preferred outcome measure and deliver utility. The QALY is the preferred health outcome measure in cost utility studies almost in every European countries, however only the English and Scottish guidelines require only EQ-5D profile to deliver utility. In the new version of the Hungarian guideline the discount rate will be changed from 5% to 3,7%, the cost-effectiveness threshold will be explicitly determined (twofold and threefold of GDP per capita) and the direct comparisons will be preferred instead of indirect comparisons. CONCLUSIONS: Generally we concluded that the Hungarian guideline published in 2002 and also the new modified version basicly require the same approach and expectations as the European ones. Change in three main things (discount rate, cost-effectivess threshold, direct comparison preference) makes our guidelines more elaborated that could help the rational decision-making. The explicitly determined cost-effectiveness threshold requires specification in the method of delivering utility in the future.
OBJECTIVES: Swiss Health Technology Assessment (HTA) initiatives have been fragmented, and official HTA processes by the Federal Office of Public Health (Bundesamt fuer Gesundheit, BAG) have been limited to new technologies and impaired by the absence of a clear-cut separation of assessment and appraisal. METHODS: Therefore, santésuisse (the national association of sick funds) and Interpharma (representing the interests of the Swiss research-based pharmaceutical industry) initiated "SwissHTA", a transparent and inclusive project designed to develop a national consensus how Switzerland might better use HTAs. The process was led by a project team, with membership from santésuisse (and Helsana), Interpharma (and Roche), the Swiss federal government (BAG), the Swiss Medical Association (FMH), and the Swiss Academy of Medical Sciences (SAMW). After seven retreats of the project team and three workshops in the course of 12 months, the team reached a consensus. RESULTS: The Swiss HTA consensus statement emphasizes the need for a broad technology focus (covering both new and existing ones by specific approaches following a common set of core principles) and recommends opportunities for stakeholder involvement throughout the HTA processes. Primary evaluation criteria should be determined by the social preferences of the Swiss population, constrained by a prior normative commitment in line with constitutional provisions and the principled, rights-based legal tradition of Switzerland. The full range of health-related benefits should be evaluated, and assessment of clinical evidence should take into account the level of evidence that can reasonably be expected in a given context, rating the degree of confidence in outcomes in relation to the relevance and the magnitude of the effects observed. Economic viability should be evaluated based on budgetary impact and cost benefit ratios, whereas the consensus rejects the idea of uniform cost per QALY benchmarks. CONCLUSIONS: The Swiss HTA consensus combines a pragmatic approach with well-defined evolutionary options.
PHP171

HTA PRINCIPLES INCLUSION IN NEW EUROPEAN UNION MEMBER STATES
Tomek D 1 , Visnansky M 2 , Marusakova E 3 1 Pharmaceutical Faculty at Comenius University, Bratislava, Slovak Republic, 2 SLOVAHTA, Bratislava, Slovak Republic, 3 GlaxoSmithKline Slovakia, Bratislava, Slovak Republic OBJECTIVES: HTA has the increasing role in decision-making process in new EU member states. Health care systems miscellaneousness causes differences in HTA exploitation and its characteristics. Our objective was to make an overview of HTA within these countries to show similarities and its differences. METHODS: Literature search was done on governmental and governmental like sites to find HTA related Acts, regulation, guidelines or other relevant documents which describes HTA country specific approach in new EU member states. First search was relevant to presence of HTA. In those of them where HTA is defined in legislation we compared several characteristics: model, role, type of HTA, role of pharmacoeconomic, threshold, discounting factor, sensitivity analysis and differentiation of approaches between therapeutic and prophylactic approaches. RESULTS: Out of 12 new EU member states (accessed in May 2004 or later) 10 applies HTA, 8 as light version, 2 as robust NICE like version. HTA has impactful position in 5 of them (Poland, Slovenia, Slovakia, Estonia and Latvia). Only Poland applies full HTA approach. Rest of countries use narrow pharmacoeconomic approach. Threshold is officially published in primary legislation in 2 countries (Poland, Slovakia). Discounting factor varies between 3% and 5%. There was no difference recognized in evaluation of either therapeutic or prophylactic approaches. CONCLUSIONS: HTA form and role differ in new EU member states, but some similarities were identified. These similarities cannot presume any transferability of HTA decision, as it depends on the other factors like health care system, composition of costs and methods of its reimbursement by different bodies within relevant country. But certain common areas for cooperation could be established based on that.
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PHP172 CHALLENGES IN DEVELOPING A NEW SYSTEM FOR REGISTRATION OF PATIENT REGISTRIES
Gliklich R 1 , Levy D 1 , Campion DM 1 , Leavy MB 1 , Karl J 1 , Berliner E 2 , Khurana L 1 , Hossfeld W 1 1 Outcome, A Quintiles Company, Cambridge, MA, USA, 2 Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA OBJECTIVES: Patient registries are an important tool for many types of clinical research, including studies of comparative effectiveness, cost effectiveness, treatment patterns, patient outcomes, and natural history of disease. Use of registries is increasing, but there is no central database in the U.S. designed specifically to list patient registries. A searchable public database that is designed to provide information about patient registries would support research collaborations, reduce redundancies, encourage the efficient use of resources, and improve transparency in observational clinical research. The goal of this project, funded by the Agency for Healthcare Research and Quality, is to design and develop a Registry of Patient Registries (RoPR) system that meets the needs of a diverse set of stakeholders. METHODS: Stakeholders from a broad range of organizations and with varying levels of familiarity with patient registries were identified and invited to participate in a series of remote and in-person meetings to gather and refine the RoPR system requirements. Requirements were also revised through public comment and usability and pilot testing. Over 320 individuals participated in RoPR design activities. RESULTS: Stakeholders identified a range of challenges facing the RoPR system. Challenges include improving understanding of the distinction between observational studies, patient registries, and other types of clinical research; determining how to provide useful information to assess registry quality; ensuring that registry listings are sufficiently complete; and motivating registry sponsors to list their registries in a voluntary system. CONCLUSIONS: In response to stakeholder feedback, the RoPR was designed as an integrated system with ClinicalTrials.gov that collects information on registry purpose, classification, objectives, data collected, progress reports, and interest in collaboration and data sharing. Some challenges identified through stakeholder discussions were addressed in the system design. Other challenges must be addressed through education and collection of stakeholder feedback following the RoPR launch in September 2012. OBJECTIVES: Disability is a global public health priority strongly related to socioeconomic status (SES). Social capital (SC) is a complex construct and little is known about how it relates to SES and disability in a middle-income country. This study's purpose was to explore this relationship in Chile. METHODS: Cross-sectional analysis of Chilean National Health Survey-2010 (nϭ5037). Health outcome: Composite index of disability (continuous variable, range 0-100). Dependent variables: a) SES measures: household income per capita (tertiles), educational level (primary/secondary/higher), employment status (yes/no), and household assets index (tertiles). b) SC dimensions: interpersonal trust (3 variables), financial/emotional support (2 variables) and social participation (2 variables). After factor analysis, s 2 factors explained 60% variance (low uniqueness in all variables), with exception of social participation which was assess separately. After orthogonal-varimax-rotation, 2 continuous aggregated variables were considered for analysis: trust and social support. Kaiser-Meyer-Olkinϭ0.62; Cronbach alphaϭ0.64 and 0.78 for trust and social support, respectively. c) Demographic factors: age, sex, marital status, rural/urban Weighted multiple linear regression models analyzed in R. Confounding and multiple interactions terms were explored. RESULTS: Mean of disability was 18.8pts. A significant crude association between disability and SES was observed. All dimensions of SC were significantly associated with disability (Trust: Ϫ7.6pts, Support: Ϫ10.7pts, Participation:Ϫ2.0pts). Adjusted regressions showed SES reduced the magnitude of its association to disability by 70% when dimensions of SC were added to the model, but remained significant. Social participation lost statistical significance in presence of SES. Multiplicative interaction terms were found between SC and education, providing additional higher chance to be disabled when being poorly educated and having low trust and support. CONCLUSIONS: There is a complex relationship between disability, SES and SC. Interactions between SES and SC significantly modify the chance of being disabled and this needs further consideration in the context of a middle-income country. 
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PHP173 DISENTANGLING THE RELATIONSHIP BETWEEN DISABILITY, SOCIOECONOMIC STATUS AND SOCIAL CAPITAL IN CHILE: A POPULATION-BASED STUDY
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